Oct 1 (Reuters) – ENSEM THERAPEUTICS: * ENSEM THERAPEUTICS ANNOUNCES ETX-636 GRANTED FAST TRACK DESIGNATION BY THE FDA FOR ADVANCED BREAST CANCER Source text: Further company coverage: [ ]

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post BRIEF-Ensem’S ETX-636 Gets FDA Fast Track For Advanced Breast Cancer appeared first on The Sunday Guardian.

See Full Page